BPC-157 dosage reference: typical range 250 – 500 mcg, Daily to 2× daily, cycle 4–8 weeks acute; 2 weeks/month maintenance. Titration chart, reconstitution…
Derived from a protective protein found in gastric juice. Legendary for healing tendons, ligaments, muscles, and gut. The most popular healing peptide.
Published protocol literature for BPC-157 describes a typical range of 250 – 500 mcg, dosed daily to 2× daily, over a cycle of 4–8 weeks acute; 2 weeks/month maintenance. Reported half-life: approximately 4 hours (subcutaneous, animal models).
| Parameter | Reported value |
|---|---|
| Typical dose range | 250 – 500 mcg |
| Frequency | Daily to 2× daily |
| Cycle length | 4–8 weeks acute; 2 weeks/month maintenance |
| Half-life | Approximately 4 hours (subcutaneous, animal models) |
| Route | Subcutaneous injection (most published protocols) |
| Diluent | Bacteriostatic water |
| Commonly stacked with | TB-500 (the "Wolverine Stack"), GHK-Cu, Pentadecapeptide |
Protocols are usually titrated rather than started at the top of the range. The tiers below reflect how BPC-157 dosing is commonly stepped in the published protocol literature.
| Tier | Dose | Frequency | Notes |
|---|---|---|---|
| Beginner | 250 mcg | Daily (near injury or systemic) | Entry-level healing support |
| Intermediate | 250–500 mcg | 2× daily | Accelerated tissue repair |
| Advanced | 500 mcg | 2× daily (local + systemic) | Maximum healing; oral for gut issues |
Concentration in mcg/mL equals vial milligrams multiplied by 1000, divided by the millilitres of bacteriostatic water added. Volume per dose in mL equals the target dose in mcg divided by that concentration. On a U-100 insulin syringe, multiply the volume in mL by 100 to read the units.
| Vial | Bacteriostatic water | Resulting concentration |
|---|---|---|
| 2 mg vial | 1 mL bacteriostatic water | 2,000 mcg/mL |
| 5 mg vial | 1 mL bacteriostatic water | 5,000 mcg/mL |
| 10 mg vial | 2 mL bacteriostatic water | 5,000 mcg/mL |
| State | Conditions | Shelf life |
|---|---|---|
| Lyophilized (Powder) | Refrigerate 2–8°C (36–46°F) or freeze | 12–24 months refrigerated; longer frozen |
| Reconstituted | Refrigerate 2–8°C only; no freezing | 21–30 days typically |
| In Transit | Insulated packaging; ice packs | Minimize time; avoid heat exposure |
| MK-677 (Oral) | Room temp okay; cool/dry preferred | Per manufacturer; typically 12+ months |
Dose ranges on this page summarise published research and practitioner protocol literature for BPC-157. They are a reference, not medical direction. All peptide products referenced are intended solely for research, investigational, or licensed professional use. They are not FDA-approved and are not intended to diagnose, treat, cure, or prevent any disease. Consult a licensed medical practitioner before any personal or clinical use.
Published protocol literature for BPC-157 generally describes 250 – 500 mcg, administered daily to 2× daily. Individual protocols vary and should be set by a licensed practitioner.
Daily to 2× daily. Frequency is driven by half-life — BPC-157 has a reported half-life of approximately 4 hours (subcutaneous, animal models), so shorter-acting compounds are dosed more often.
Typical cycle length reported is 4–8 weeks acute; 2 weeks/month maintenance. Cycling exists to limit receptor desensitisation and to create assessment windows, not as a fixed rule.
2mg → 1ml bacteriostatic water; 5mg → 1ml bacteriostatic water; 10mg → 2ml bacteriostatic water. Concentration in mcg/mL equals vial milligrams times 1000 divided by millilitres of bacteriostatic water.
BPC-157 is studied primarily for soft-tissue healing, tendon and ligament repair, and gastrointestinal protection in animal models.
No. BPC-157 is not approved by the FDA for any human use and is sold for research, investigational, or licensed professional use only.